June 15, 2026 Activision Blizzard, Inc. Notice of June 30, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
June 15, 2026 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
June 15, 2026 Georgia’s Plant Hatch receives 20-year license renewal from the Nuclear Regulatory Commission
